Finance

Lists
Why is ACRS down 4.28%?
Dive Deeper
ACRS:NASDAQ
Aclaris Therapeutics Inc
$5.15
-4.28%
(-0.23) 1D
$5.25
+1.94% (+0.100)
After hours
Closed: Sep 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRS...
Open
$5.39
High
$5.54
Low
$5.10
Mkt. cap
758.07M
Avg. vol.
2.33M
Volume
1.47M
52-wk high
$6.60
52-wk low
$1.74
EPS
-$0.59
Beta
0.79
Shares outstanding
147.20M
No. of employees
71
Open
$5.39
High
$5.54
Low
$5.10
Mkt. cap
758.07M
Avg. vol.
2.33M
Volume
1.47M
52-wk high
$6.60
52-wk low
$1.74
EPS
-$0.59
Beta
0.79
Shares outstanding
147.20M
No. of employees
71
News stories
From web sources and news partners
About Aclaris Therapeutics Inc
CEO-
Employees71
Founded2012
Headquarters-
SectorPharmaceutical industry
Websiteaclaristx.com
Analyst ratings
Based on 5 analysts giving stock ratings to ACRS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ACRS in the last 3 months.
Highest
Current $5.15
$16.00 (+210.68%)
Average
$12.00 (+133.01%)
Lowest
$10.00 (+94.17%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Nash
Canaccord Genuity
Buy
Initiated
$10.00
+94.2%
09/01/2026
Biren Amin
Piper Sandler
Buy
Maintained
$11.00
+113.6%
08/31/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$16.00
+210.7%
08/10/2026
Kate Dellorusso
LifeSci Capital
Buy
Maintained
$13.00
+152.4%
08/06/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$10.00
+94.2%
08/06/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$12.00
+133%
05/11/2026
Martin Fan
Wedbush
Buy
Maintained
$10.00
+94.2%
05/08/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$10.00
+94.2%
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
$4.00
-22.3%
05/08/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
$10.00
+94.2%
04/16/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.15 / -$0.16
+4.54%beat
Revenue / Est. (USD)
1.63M / 1.54M
+6.11%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.30M
1.30M
2.00M
1.63M
Cost of goods sold
15.48M
18.05M
17.44M
19.52M
Cost of revenue
15.48M
18.05M
17.44M
19.52M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.87M
5.58M
6.74M
6.05M
Operating expense
4.87M
5.58M
6.74M
6.05M
Total operating expenses
20.35M
23.63M
24.19M
25.57M
Operating income
-17.05M
-22.33M
-22.19M
-23.94M
Other non operating income
716.00K
1.30M
854.00K
972.00K
EBT including unusual items
-14.61M
-19.80M
-19.82M
-21.50M
EBT excluding unusual items
-14.51M
-19.40M
-19.82M
-21.20M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.61M
-19.80M
-19.82M
-21.50M
Net profit margin
-442.98%
-1,528.57%
-993.19%
-1,320.13%
Earnings per share
-0.12
-0.16
-0.15
-0.15
Interest and investment income
1.82M
1.63M
1.51M
1.76M
Interest expense
-
-
-
-
Net interest expenses
1.82M
1.63M
1.51M
1.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.04M
-22.32M
-22.19M
-23.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps